What Do We Know About Heart Failure Phenotypes and Personalized Treatment? A Science-Based Overview

Image generated by AI

When a cardiologist tells a patient they have heart failure, they’re using an umbrella term that conceals a bewildering diversity of underlying diseases. Two patients with identical symptoms—shortness of breath, fatigue, swollen ankles—may have entirely different physiological problems requiring opposite treatment strategies. This contradiction between uniform diagnosis and radically different biology has driven a quiet revolution in cardiology over the past decade: the recognition that heart failure is not one disease, but many, and that effective treatment requires matching the right drug to the right patient phenotype.

Heart failure affects over 6 million Americans and kills more people than all cancers combined, yet treatment remains frustratingly one-size-fits-all for many patients. Recent advances in molecular biology, imaging technology, and data science have revealed that heart failure phenotypes—distinct biological subtypes with different causes, mechanisms, and prognoses—respond dramatically differently to the same medications. This growing understanding is reshaping how doctors diagnose and treat heart disease, moving cardiology away from symptom-based treatment toward mechanism-based precision medicine that could transform outcomes for millions of patients worldwide.

What Is Heart Failure Phenotypes and Personalized Treatment?

Heart failure occurs when the heart cannot pump enough blood to meet the body’s needs, but the mechanisms underlying this failure vary profoundly. A phenotype is an observable characteristic—the actual expression of disease in a patient—and heart failure phenotypes represent distinct biological patterns that can be identified through clinical assessment, biomarkers, imaging, and molecular profiling. The key insight driving modern cardiology is that two patients presenting with nearly identical symptoms may have completely different underlying problems: one might have a stiff, inflexible heart chamber, while another’s heart muscle is actually weak and dilated. Personalized treatment means tailoring therapeutic strategies to each patient’s specific phenotype rather than applying generic protocols based on symptoms alone.

The conceptual framework for heart failure phenotyping has evolved dramatically since the 1970s, when cardiologists primarily distinguished between systolic heart failure (weak pumping) and diastolic heart failure (stiff ventricles). The pioneering work of researchers like Dr. Margaret Redfield at Mayo Clinic and Dr. Gregg Fonarow at UCLA in the 2000s revealed that diastolic dysfunction was far more common than previously believed, affecting nearly half of all heart failure patients, yet receiving minimal research attention. Over the past fifteen years, technological advances in genomic sequencing, proteomics, cardiac imaging, and wearable monitoring have enabled scientists to subdivide these broad categories into increasingly specific phenotypes based on ejection fraction, structural remodeling, inflammatory markers, fibrosis patterns, metabolic dysfunction, and genetic predisposition, laying the groundwork for precision medicine approaches.

What the Research Shows

The heart maintains function through a delicate balance between contractility (the force of contraction), compliance (how easily the chamber fills), and electrical coordination. When this balance fails, multiple pathological pathways can be activated. In heart failure with reduced ejection fraction (HFrEF), the left ventricle becomes enlarged and weakened, often following a myocardial infarction or years of high blood pressure, and contractile proteins fail to generate adequate force. Conversely, in heart failure with preserved ejection fraction (HFpEF)—which now represents over half of all heart failure cases—the ventricle maintains normal pumping strength but becomes stiff and cannot relax properly, making it difficult to fill with blood. Between these poles exist intermediate phenotypes with mildly reduced ejection fraction, each involving distinct molecular abnormalities affecting calcium handling, mitochondrial function, immune activation, and extracellular matrix remodeling.

Consider the analogy of a weakened building versus a rigid one: HFrEF resembles a structure with crumbling support columns that cannot bear load, while HFpEF resembles a building made of unyielding concrete that cannot accommodate normal settling and movement. A damaged column requires reinforcement, while rigid concrete needs to become more flexible—fundamentally opposite solutions. Similarly, HFrEF patients may benefit from beta-blockers and ACE inhibitors that reduce the workload on failing muscle, while HFpEF patients often need diuretics to reduce congestion and anti-inflammatory agents to address the stiffness. Recent molecular research reveals that HFpEF frequently involves systemic inflammation, endothelial dysfunction, and impaired nitric oxide signaling, creating entirely different therapeutic targets than the neurohormonal dysregulation characteristic of HFrEF.

What This Means for Patients and Science

The clinical implications are profound and rapidly expanding. Previously, a patient diagnosed with heart failure received a standardized drug regimen regardless of their specific phenotype; today’s precision approach involves comprehensive phenotyping to identify the dominant pathological mechanism, enabling targeted intervention. Biomarkers like B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) indicate hemodynamic stress, while troponins reflect myocardial injury, and emerging biomarkers like soluble ST2 and galectin-3 predict fibrosis and remodeling. High-sensitivity cardiac troponin assays, available in many hospitals, can now detect myocardial injury months or years before symptoms appear, enabling early intervention. Echocardiography combined with strain imaging reveals not just ejection fraction but subtle patterns of dysfunction, while cardiac MRI can detect myocardial fibrosis and infiltration that guides treatment decisions.

Major medical centers are now establishing heart failure phenotyping protocols using multimodal assessment—combining clinical history, laboratory biomarkers, advanced imaging, genetic testing, and wearable device data to construct a detailed biological profile of each patient. The American College of Cardiology and American Heart Association have updated guidelines emphasizing precision diagnosis, recommending comprehensive evaluation beyond ejection fraction. Pharmaceutical companies have shifted research toward phenotype-specific therapies: SGLT2 inhibitors (originally developed for diabetes) showed surprising efficacy in HFpEF patients in the 2021 DELIVER trial, while finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated benefits specifically in HFpEF with chronic kidney disease in the FINEARTS-HF trial. These successes validate the underlying hypothesis that matching drug mechanisms to patient phenotypes yields superior outcomes.

Recent Breakthroughs in Heart Failure Phenotypes and Personalized Treatment

The past three years have witnessed remarkable acceleration in heart failure phenotyping science. The 2023 ACC/AHA Heart Failure Guidelines formally incorporated phenotype-based treatment algorithms, moving beyond ejection fraction as the organizing principle and instead organizing care around specific pathophysiological patterns. The landmark DELIVER trial (2022) and subsequent FINEARTS-HF trial (2023) demonstrated that SGLT2 inhibitors benefit HFpEF patients, a population that historically had almost no disease-modifying therapies—a discovery that fundamentally challenged the HFrEF-centric treatment paradigm. Machine learning algorithms trained on thousands of patient datasets have begun identifying novel phenotype clusters that don’t neatly fit traditional categories, revealing cryptic subtypes characterized by unique combinations of metabolic dysfunction, microvascular disease, and fibrosis patterns that predict differential drug responses.

Researchers are currently investigating several promising frontiers. Advanced proteomic analysis can now measure thousands of circulating proteins simultaneously, revealing individualized inflammation and fibrosis signatures that predict who will respond to immunomodulatory therapy. Single-cell RNA sequencing of myocardial biopsies is uncovering distinct immune cell infiltration patterns in different heart failure phenotypes, suggesting that immunotherapy might benefit certain subgroups while harming others. Longitudinal studies using continuous cardiac monitoring through implantable devices are revealing dynamic phenotype transitions—patients shifting from one pathophysiological state to another—that require treatment adjustment. Integration of social determinants of health, genetic ancestry, and environmental exposures into phenotyping algorithms is beginning to address cardiovascular health disparities, particularly the underrepresentation of non-European ancestry patients in clinical trials.

Why Heart Failure Phenotypes and Personalized Treatment Matters for the Future

The shift toward phenotype-based medicine represents a fundamental reorientation of cardiology toward precision science with implications far beyond heart failure. If cardiologists can reliably match patients to treatments based on underlying mechanisms rather than superficial symptoms, the model becomes generalizable to other complex diseases like cancer, autoimmune disease, and neurodegeneration. The success of SGLT2 inhibitors in HFpEF, discovered through mechanism-based phenotyping rather than traditional disease-focused drug development, has already sparked trials in chronic kidney disease, diabetes, and even pulmonary hypertension—demonstrating that phenotype-specific insights generate insights applicable across disease boundaries. As healthcare systems increasingly adopt electronic health records with integrated molecular, imaging, and clinical data, the infrastructure for real-time phenotyping and algorithmic treatment matching becomes technically feasible at scale.

However, significant challenges remain before phenotype-based precision medicine becomes routine practice. Not all hospitals have access to advanced imaging, biomarker testing, or genetic sequencing necessary for comprehensive phenotyping, creating risk of widening healthcare disparities. The mechanistic heterogeneity of heart failure is so profound that true precision medicine may require dozens of distinct treatment algorithms, complicating clinical practice and pharmaceutical development. Temporal dynamics pose another puzzle: a patient’s phenotype may shift as disease progresses or following treatment, requiring continuous reassessment. Regulatory frameworks for precision medicine remain unsettled—the FDA typically approves drugs for diagnostic categories rather than continuously-defined phenotypes, creating legal and reimbursement complexities. Finally, the vast majority of heart failure phenotyping research involves populations of European ancestry, raising urgent questions about whether mechanistic insights and treatment responses generalize to more diverse genetic backgrounds and environmental contexts.

Key Takeaways

• Heart failure is not a single disease but a syndrome encompassing multiple distinct phenotypes with different mechanisms, causes, and treatment responses, ranging from weakened muscle in HFrEF to stiffened ventricles in HFpEF.
• Modern heart failure phenotyping integrates clinical assessment, biomarkers, advanced imaging, genetic testing, and molecular profiling to identify the specific pathophysiological mechanisms in individual patients, enabling mechanism-matched rather than symptom-based treatment.
• Recent clinical trials have demonstrated that SGLT2 inhibitors and other phenotype-targeted therapies dramatically improve outcomes in specific heart failure subtypes, validating the precision medicine approach and revealing previously invisible therapeutic opportunities.
• Heart failure phenotyping research is rapidly advancing through machine learning analysis of large datasets, single-cell sequencing of myocardial tissue, proteomic profiling of circulating biomarkers, and continuous monitoring through implantable devices, revealing novel disease subtypes and dynamic phenotype transitions.
• Phenotype-based precision medicine in cardiology holds transformative potential for healthcare systems worldwide, potentially doubling or tripling treatment efficacy for millions of patients while establishing generalizable frameworks for precision medicine applicable to other complex diseases.